This is Archived Content

This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA).
View current meetings on


May 26, 2010 - 12:00am
Neuroscience Center, Rockville, Maryland


Jeff Schulden, M.D.
Division of Epidemiology, Services and Prevention Research, NIDA

Strategic Goals Guiding the CTSA Consortium:

To set a national research agenda, five overarching strategic goals guide CTSA Consortium activities:

  • Goal 1: Build national clinical and translational research capability
  • Goal 2: Provide training and improve career development of clinical and translational scientists
  • Goal 3: Enhance consortium-wide collaborations
  • Goal 4: Improve the health of our communities and the nation
  • Goal 5: Advance T1 translational research to move basic laboratory discoveries and knowledge into clinical testing
This is a map of the United States that shows the CTSA sites. Specifically, there are 46 CTSA institutions which are red blocks on the map, and the CTSA states are shaded in purple. There is currently a total of 46 CTSA institutions and 26 CTSA states.

Background and Meeting Goals:

  • CTSA Consortium has broad vision to transform how clinical and translational research conducted in the U.S., building enhanced infrastructure for multidisciplinary researchers and clinicians to perform research more effectively
  • Through this meeting we sought to bring together CTSA leadership and drug abuse researchers to discuss ways to strengthen the integration of drug abuse research as part of the CTSA Consortium's efforts
  • Sessions included presentations on current drug abuse research initiatives at CTSA sites along with discussions on ways to develop additional drug abuse research programs in cooperation with the CTSA Consortium

Highlights: Wide Range of Routes for SUD Researchers to Engage CTSA Sites

  • Broad supports for research development, including:
    • Research networking
    • Brokering research partnerships
    • Consultations for protocol development, including statistical support, informatics support, guidance on IRB process
  • Access to practice-based research networks, including community-based clinical networks
  • Access to electronic data warehouses, enhanced EMR systems
  • Access to consolidated genomic and proteomic data
  • Funding for pilot studies programs
  • Research training grants for junior investigators (KL2 mechanism under auspices of CTSA U54)